Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes

What Was Tested

The paper reports a study of Insulin Lispro, published as a randomized controlled trial.

Insulin lispro is a rapid-acting analog of human insulin that can be used to target the postprandial rise in plasma glucose.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

In the other arm, patients used a combination therapy with insulin lispro before meals and sulfonylureas.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The patients were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Nothing was hidden in this open-label Insulin Lispro study: the patients and staff both knew the treatment.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

Fasting plasma glucose (FPG) and 1- and 2-h postprandial glucose (after a standardized meal), HbA1c, total, HDL, and LDL cholesterol, and triglyceride levels were measured at the end of each arm of the study.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, C-Peptide, Cholesterol, Cholesterol, HDL, Diabetes Mellitus, Type 2, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.